View all companies
Recommendation
Start reading our world-class research today.
Already have an account?
Log in
9 articles for ACME Laboratories
IDLC-SL Pharma Sector Update: For the quarter ended Q1 FY23
Single digit industry revenue growth in Q1 FY23 can be attributed to the base effect of Q1 FY22. Gross margin fell likely as a result of costly API purchases due to BDT depreciation. Rise in opex to sales is likely the result of inflationary pressure...
Tanay Kumar Roy @ IDLC Securities 13 December 2022
Flash Report /
Global
Bangladesh: Manufacturing firms to get relief due to rate cap and tax cut
Manufacturing and industrial companies to enjoy the interest rate cap. We expect this interest rate cap to affect the profitability of several listed companies. Please note that the regulator intended to formulate the policy before the pandemic to re...
Tanay Kumar Roy @ IDLC Securities 12 August 2020
ACME Laboratories: Q3 FY20 earnings decline by c4% yoy despite c17% yoy revenue growth
Contribution from the new projects generated c17% yoy revenue growth. During the first half of FY20, the company generated 14.5% yoy top-line growth on an average. Even though the company generated significant revenue growth and improved gross margin...
Tanay Kumar Roy @ IDLC Securities 9 June 2020
Bangladesh pharmaceuticals: Unique sales trend, rate cap lessen Covid-19 impact
The long holiday ended; business activities cautiously re-opened on 31 May. The 66 days of holiday, which started in late March, comprised 38 days of general holiday (ie lockdowns), 20 weekends, and 8 public holidays. We may see a 20% average increas...
Tanay Kumar Roy @ IDLC Securities 3 June 2020
Flash Report /
Bangladesh
Bangladesh Pharma: Minimal impact on sector from Ranitidine restrictions
According to a press report, the Directorate General of Drug Administration (DGDA) of Bangladesh temporarily restricted the import of raw materials from two Indian companies – Saraca Laboratories Limited and Dr Reddy’s Laboratories –for the productio...
Tanay Kumar Roy @ IDLC Securities 30 September 2019
Three reasons to invest in Bangladesh pharmaceuticals now
1) Increase in drug prices; we upgrade RENATA from Hold to Buy. Likewise, SQUARE has increased the prices of three brands, weighing roughly 15% of total sales, by c14% on an average. Therefore, we expect a 100bps expansion in EBITDA margin for SQUARE...
Tanay Kumar Roy @ IDLC Securities 11 September 2019
Details
Bangladesh
Asia
Pharmaceuticals, Biotechnology & Life Sciences
About
The Acme Laboratories Ltd. is a pharmaceutical company. The Company manufactures, fabricates, and processes drugs for therapeutic categories which include anti-infective, cardiovascular, antidiabetics, gastrointestinal, CNS, and respiratory disease among others.
